Remove topic formulation
article thumbnail

With global expansion planned, Krystal lays out blockbuster ambitions for topical gene therapy

Fierce Pharma

Not even one year after becoming a commercial biotech, Krystal Biotech has blockbuster dreams for its flagship product. | In its first six months of commercial availability, Krystal's topical gene therapy Vyjuvek raked in more than $50 million.

105
105
article thumbnail

Sun Pharma Canada’s Winlevi rolls out in Canada

Drug Store News

Winlevi is the first and only topical androgen receptor inhibitor, and the newest Health Canada-approved formulation to target the hormonal component of acne in 40 years.

52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Soligenix and Silk Road sign deal for Behçet’s disease treatment rights

Pharmaceutical Technology

Soligenix has signed an exclusive option agreement with Silk Road Therapeutics for the right to acquire Pentoxifylline (PTX) topical formulation intended to treat mucocutaneous ulcers in Behçet’s disease (BD) patients. The firms did not divulge the terms of the deal. They also used their standard colchicine regimen.

52
article thumbnail

QA of prostaglandin analogues for glaucoma treatment

European Pharmaceutical Review

A paper, published in the European Journal of Pharmaceutical Sciences identified the quality assurance (QA) challenges and trends of analytical techniques in ocular drug delivery and formulation, focusing on treatments for glaucoma. al focuses on formulations using substances such as prostaglandin F2 alpha (PGF2?) for latanoprost.”

Dosage 90
article thumbnail

Eyenovia and Formosa partner for new ophthalmic therapeutics

Pharmaceutical Technology

The collaboration will combine the Optejet dispensing technology of Eyenovia with the APNT nanoparticle formulation platform of Formosa to develop topical therapeutics. The Optejet microdose formulation and delivery platform use Microdose Array Print (MAP) technology for delivering 6ml-8ml of the drug.

FDA 59
article thumbnail

Breaking Down the 2024 PRITE Blueprint

Board Vitals - Pharmacist

The PRITE covers a broad range of topics within the field of psychiatry. Administered annually, it covers a wide array of topics to ensure a well-rounded evaluation of a resident’s understanding of psychiatry. What is the PRITE ? What is the PRITE ? Let’s break down the latest PRITE blueprint : A.

98
article thumbnail

US FDA grants approval to Incyte’s Opzelura cream for vitiligo treatment

Pharmaceutical Technology

as a topical treatment of nonsegmental vitiligo in adults and paediatric patients aged 12 years and above. Opzelura is a topical formulation of a Janus kinase (JAK) inhibitor. In non-segmental vitiligo patients, it is indicated for continuous topical use twice a day to affected regions of up to 10% body surface area.

FDA 116